Securing Two Pillars in Muscle-Enhancing Anti-Obesity Drugs
A Differentiation Strategy with Peptide-Based, Not Antibody-Based, Treatments

Hanmi Pharmaceutical unveiled its muscle-enhancing anti-obesity drug, ‘LA-MSTN (HM500197),’ for the first time at the American Diabetes Association (ADA 2026) held in New Orleans, USA.


Seon Myung Lee, Senior Researcher and Team Leader of the Future Growth Division at Hanmi Pharm, gave an oral presentation on April 7 (local time) at the American Diabetes Association (ADA 2026), based on a poster containing key research data on HM17321, the world's first obesity treatment that increases muscle mass. Hanmi Pharm

Seon Myung Lee, Senior Researcher and Team Leader of the Future Growth Division at Hanmi Pharm, gave an oral presentation on April 7 (local time) at the American Diabetes Association (ADA 2026), based on a poster containing key research data on HM17321, the world's first obesity treatment that increases muscle mass. Hanmi Pharm

View original image

On June 16, Hanmi Pharmaceutical announced that the ADA 2026 presentation venue was crowded with attendees eager to learn about the muscle-enhancing anti-obesity drug. Researchers and leading corporate representatives from around the world in the field of obesity metabolism showed great interest in the development strategies, differentiating features, and preclinical results of the innovative obesity treatments HM17321 and HM500197. Following the presentation, there were numerous questions about the future development roadmap and commercialization strategies. According to the company, some global corporations even requested separate meetings.


Recently, the key issue in obesity metabolism has become “high-quality weight loss”—reducing body fat while maintaining or enhancing muscle mass—as a next-generation treatment strategy. Currently, GLP-1-based anti-obesity drugs provide about 15 to 20% weight loss, but up to 40% of this lost weight is due to muscle loss, which is a significant limitation. There are also concerns about side effects such as weight rebound (yo-yo effect) after discontinuing the drug.


Against this backdrop, combination studies targeting the myostatin and activin pathways—which are involved in muscle growth—are gaining attention. However, current development candidates in the industry are limited to antibody and Fc fusion protein-based approaches.


HM500197, a peptide-based drug, is designed to selectively inhibit myostatin, thereby increasing lean body mass primarily in skeletal muscle, representing a next-generation muscle-enhancing therapy. Unlike antibody-based drugs, it can be easily developed in combination or as a co-formulation with incretin-based therapies of the same modality, which is expected to significantly improve patient convenience.


At this conference, Hanmi Pharmaceutical presented data showing that HM500197 demonstrated myostatin inhibition activity comparable to that of the antibody-based muscle-preserving drug bimagrumab in in vitro studies, while exhibiting no inhibitory activity against non-target cytokines, indicating excellent myostatin selectivity.


The company also reported that, in in vivo studies, HM500197 showed superior efficacy in selectively increasing skeletal muscle lean mass compared to bimagrumab. It also minimized off-target effects, thereby providing differentiated safety results.


Notably, in a high-fat diet-induced obese mouse model, HM500197 dose-dependently increased lean mass, especially skeletal muscle mass. When administered in combination with a GLP-1-based drug, it effectively suppressed muscle loss while promoting fat-centric weight loss, providing scientific evidence to support its therapeutic potential for “high-quality weight loss.”


Hanmi Pharmaceutical’s muscle-enhancing anti-obesity drug, ‘LA-UCN2 (HM17321),’ is currently undergoing a Phase 1 clinical trial in the United States. At this conference, the company presented seven broad and innovative research results that explored, in depth, the potential for combination with various mechanism-based drugs, as well as the drug’s mechanisms of action in the body, and its therapeutic potential in musculoskeletal, cardiovascular, and renal protection areas.



Choi Inyoung, Executive Vice President and Head of the Future Growth Division at Hanmi Pharmaceutical, stated, “Starting with efeglenatide, the Korea-developed anti-obesity drug created with proprietary technology, we have established a customized anti-obesity treatment portfolio through the ‘H.O.P Project,’ which includes next-generation triple agonists (LA-GLP/GIP/GCG, HM15275, Phase 2), HM17321 (Phase 1), and HM500197.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing